{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T01:29:22Z","timestamp":1777858162862,"version":"3.51.4"},"reference-count":45,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2003,6,1]],"date-time":"2003-06-01T00:00:00Z","timestamp":1054425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2003,6]]},"abstract":"<jats:p>While atypical antipsychotics appear to be effective in reducing depressive symptoms in the acute phase of schizophrenia, little is known about their efficacy in patients with ongoing symptoms. The present study assessed whether quetiapine (Seroquel\u00ae) is more effective than haloperidol in treating depressive symptoms in patients with persistent positive symptoms, and investigated whether this effect is independent, or secondary to, reductions in other symptoms such as positive, negative or extrapyramidal symptoms. Patients with schizophrenia and a history of partial refractoriness to conventional antipsychotics who had not responded to 4 weeks of fluphenazine treatment (20 mg\/day) were randomized to receive either quetiapine (600 mg\/day) or haloperidol (20 mg\/day) for a further 8 weeks. Change in the Positive and Negative Syndrome Scale depression factor score from baseline to endpoint was calculated and path analyses were performed on data from 269 patients. Quetiapine produced a greater reduction in depressive scores than haloperidol (-1.60 versus -0.54; p = 0.006). The path analyses indicated that this was a direct effect on depressive symptoms. These findings extend the evidence for an antidepressant effect for the novel antipsychotics in schizophrenia, and suggest that this is not limited to acutely psychotic patients.<\/jats:p>","DOI":"10.1177\/0269881103017002010","type":"journal-article","created":{"date-parts":[[2003,7,3]],"date-time":"2003-07-03T17:45:03Z","timestamp":1057254303000},"page":"210-215","source":"Crossref","is-referenced-by-count":41,"title":["Differential Effect of Quetiapine on Depressive Symptoms in Patients with                Partially Responsive Schizophrenia"],"prefix":"10.1177","volume":"17","author":[{"given":"Robin A.","family":"Emsley","sequence":"first","affiliation":[{"name":"Department of Psychiatry, University of Stellenbosch, Tygerberg, Cape                        Town, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Buckley","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Medical College of Georgia, Augusta, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. Martin","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael R.","family":"Greenwood","sequence":"additional","affiliation":[{"name":"AstraZeneca, Alderley Park, Macclesfield, UK."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2003,6,1]]},"reference":[{"key":"atypb1","unstructured":"American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn (DSM-IV). APA, Washington, DC"},{"key":"atypb2","unstructured":"Arvanitis L A, Miller B G, Kowalcyk B B (1997) Efficacy of `Seroquel' (quetiapine fumerate) in affective symptoms of schizophrenia . Scientific Abstracts of the 36th Annual Meeting of the American College of Neuropsychopharmacology, Honolulu, Hawaii"},{"key":"atypb3","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.154.4.486"},{"key":"atypb4","doi-asserted-by":"crossref","unstructured":"Barnes T R, Liddle P F, Curson D A, Patel M (1989b) Negative symptoms, tardive dyskinesia and depression in chronic schizophrenia . Br J Psychiatry 7(Supp 7): 99-103","DOI":"10.1192\/S0007125000291605"},{"key":"atypb5","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291700028488"},{"key":"atypb6","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.177.6.516"},{"key":"atypb7","unstructured":"Breier A, Buchanan R W, Kirkpatrick B (1984) Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia . Am J Psychiatry 151: 2-26"},{"key":"atypb8","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.153.6.759"},{"key":"atypb9","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(01)00247-X"},{"key":"atypb10","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v60n1105"},{"key":"atypb11","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-200015030-00001"},{"key":"atypb12","unstructured":"Goldstein J, Mullen J A, Sajatovic M (2000) Efficacy of quetiapine and risperidone against depressive symptoms in outpatients with psychotic disorders . Poster presented at the First International Forum of Mood and Anxiety Disorders, 1-3 December, Monte Carlo"},{"key":"atypb13","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/20.2.327"},{"key":"atypb14","doi-asserted-by":"crossref","unstructured":"Hellewell J S E, Kalali A H, Langham S J, McKellar J, Awad A G (1999) Patient satisfaction and acceptability of long-term treatment with quetiapine . Int J Psychiatry Clin Pract 3: 97-105","DOI":"10.3109\/13651509909024770"},{"key":"atypb15","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.151.6.773"},{"key":"atypb16","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.139.2.89"},{"key":"atypb17","doi-asserted-by":"publisher","DOI":"10.1097\/00005053-198703000-00005"},{"key":"atypb18","unstructured":"Kay S (1991) Positive and negative syndromes in schizophrenia: assessment and research . Clinical and experimental psychiatry monograph, no. 5. Brunner\/Mazel, New York"},{"key":"atypb19","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.157.6.987"},{"key":"atypb20","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.150.11.1643"},{"key":"atypb21","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(00)00002-5"},{"key":"atypb22","doi-asserted-by":"publisher","DOI":"10.1016\/S0010-440X(95)90105-1"},{"key":"atypb23","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1982.04290020051010"},{"key":"atypb24","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v58n1205"},{"key":"atypb25","unstructured":"McElroy S L, Dessain E C, Pope H G Jr, Cole J O, Keck P E Jr, Frankenberg F Ret al. (1991) Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia . J Clin Psychiatry 52: 411-414"},{"key":"atypb26","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.133.1.14"},{"key":"atypb27","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.152.2.183"},{"key":"atypb28","doi-asserted-by":"publisher","DOI":"10.1007\/BF02191543"},{"key":"atypb29","doi-asserted-by":"publisher","DOI":"10.1016\/0010-440X(94)90167-8"},{"key":"atypb30","doi-asserted-by":"crossref","unstructured":"Retherford RD, Kim Choe MK (1993) Path analysis. Statistical models for causal analysis, pp. 93-99. John Wiley and Sons, New York","DOI":"10.1002\/9781118033135"},{"key":"atypb31","doi-asserted-by":"publisher","DOI":"10.1111\/j.2044-8309.1998.tb01171.x"},{"key":"atypb32","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.142.5.465"},{"key":"atypb33","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/17.1.75"},{"key":"atypb34","doi-asserted-by":"publisher","DOI":"10.1192\/S0007125000292623"},{"key":"atypb35","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.157.9.1379"},{"key":"atypb36","doi-asserted-by":"publisher","DOI":"10.1016\/0006-3223(92)90108-C"},{"key":"atypb37","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.55.3.250"},{"key":"atypb38","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(98)00093-6"},{"key":"atypb39","unstructured":"Tollefson G D, Andersen S W (1999) Should we consider mood disturbance in schizophrenia as an important determinant of quality of life? J Clin Psychiatry 60 (Suppl 5): 23-29"},{"key":"atypb40","doi-asserted-by":"publisher","DOI":"10.1016\/0010-440X(75)90019-X"},{"key":"atypb41","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1978.01770330075006"},{"key":"atypb42","doi-asserted-by":"publisher","DOI":"10.1097\/00001648-199710000-00010"},{"key":"atypb43","unstructured":"Weiden P, Aquila R, Standard J (1996) Atypical antipsychotic drugs and long term outcome in schizophrenia . J Clin Psychiatry 57 (Suppl 11): 53-60"},{"key":"atypb44","unstructured":"World Health Organization (1992) The tenth revision of the international classification of diseases and related health problems (ICD-10). WHO, Geneva"},{"key":"atypb45","unstructured":"Zarate C A Jr, Tohen M, Banov M D, Weiss M K, Cole J O (1995) Is clozapine a mood stabilizer? J Clin Psychiatry 56: 108-112"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0269881103017002010","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0269881103017002010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:08:42Z","timestamp":1777507722000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0269881103017002010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,6]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2003,6]]}},"alternative-id":["10.1177\/0269881103017002010"],"URL":"https:\/\/doi.org\/10.1177\/0269881103017002010","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,6]]}}}